Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/cid/cis023 | DOI Listing |
Kidney Med
January 2025
Center for Global Health, Weill Cornell Medicine, New York, NY.
Rationale & Objective: Longitudinal research on chronic kidney disease (CKD) in sub-Saharan Africa is sparse, especially among people living with HIV (PLWH). We evaluated the incidence of CKD among PLWH compared with HIV-uninfected controls in Tanzania.
Study Design: Prospective cohort study.
Radiat Oncol
January 2025
Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, P.R. China.
Aim: To characterize the differences of dynamic changes for absolute lymphocyte count (ALC) among esophageal squamous cell carcinoma (ESCC) patients treated with neoadjuvant chemoradiotherapy (nCRT) with or without pembrolizumab, as well as to investigate the clinical and lymphocyte-related organs dosimetric parameters that would impact ALC nadir during nCRT.
Materials And Methods: A total of 216 ESCC patients who received nCRT (with pembrolizumab 144; without pembrolizumab: 72) were identified from a prospective cohort. Weekly and 1-month post-nCRT ALC were identified.
Intern Emerg Med
January 2025
Department of Gastroenterology, Hepatology and Transplant Medicine, Medical Faculty, University of Duisburg-Essen, Hufelandstraße 55, 45147, Essen, Germany.
Gallstones are among the most frequent hepatobiliary conditions. Although in most cases, they remain asymptomatic, they can cause complications and, in such cases, invasive treatments like endoscopic retrograde cholangiography (ERC) or cholecystectomy are required. Here, we present the results of genetic testing of a single family with a high incidence of symptomatic gallstones and cholestatic liver phenotypes.
View Article and Find Full Text PDFBackground: An easy and reliable method for detection of Alzheimer's Disease (AD) and mild cognitive impairment (MCI) is critical for clinical trial enrollment. In the era of amyloid-lowering therapies, there is a need to identify individuals likely to have amyloid to enrich recruitment and lower costs related to amyloid PET. In addition, a subset of cognitively normal individuals have amyloid deposition (Preclinical AD) but to date there is no cognitive assessment or screening method that can detect these individuals in the absence of expensive biomarkers.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Background: In the era of disease-modifying treatments for Alzheimer's disease (AD), accurate detection of underlying AD pathology is critical. Blood-based biomarkers for AD are increasingly available, but their diagnostic performance is not well-understood across the spectrum of neurodegenerative disease, especially when AD presents as co-pathology in non-AD syndromes. We investigated the diagnostic performance of three plasma biomarkers (phosphorylated tau 217 [p-tau217], neurofilament light chain [NfL], and glial fibrillary acidic protein [GFAP]) to detect AD, confirmed by autopsy, across 12 clinical neurodegenerative syndromes with various underlying etiologies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!